# BioMarin Pharmaceutical (BMRN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/BMRN
## Company Profile
- Ticker: BMRN
- Exchange: NASDAQ
- Sector: Gene Therapy
- Location: San Rafael, California
- Tags: Gene Therapy, Rare Disease Gene Therapy, Rare Disease
## Stock Data
- Close: 66.43 USD
- Market cap: 10305926234.16 USD
- Last updated: 2026-09-03
## Business Overview
BioMarin is a rare-disease biotechnology company with a portfolio built around enzyme therapies, rare disease commercialization, and pipeline expansion. It remains one of the clearest pure-play rare-disease names in public biotech.
## Why The Stock Is Moving

As of Sep 3, 2026, BMRN closed down 0.81% at $66.43. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in San Rafael, California and listed on NASDAQ, BioMarin is a U.S.-based rare-disease biotech with global commercial reach. It sits in specialty biotechnology rather than broad pharma.

## Business Model

The company generates value through orphan-drug commercialization, label expansion, and a pipeline aimed at additional rare conditions. Investors focus on product adoption, revenue growth, and the durability of the rare-disease franchise.

## Landscape Position

BioMarin occupies a premium niche within biotech because rare disease can support pricing power and durable commercial growth. It is less binary than early-stage oncology names, but data and regulatory milestones still matter.

## Future Catalysts

- BioMarin’s catalysts are Voxzogo commercial growth, Roctavian uptake, and any enzyme-therapy or gene-therapy update that helps the portfolio. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.

## Recent News
- 2016-12-12 13:29 EST — [BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia](https://biopharmsignal.com/news/BMRN/biomarin-enrolls-first-participant-in-phase-3-trial-of-vosoritide-for-treatment--dd3b13a5) — Source: BioMarin Pharmaceutical
- 2016-11-03 12:30 EST — [BioMarin to Attend Three Upcoming Investor Conferences](https://biopharmsignal.com/news/BMRN/biomarin-to-attend-three-upcoming-investor-conferences-160019b5) — Source: BioMarin Pharmaceutical
- 2016-10-27 20:03 EST — [BioMarin Announces Third Quarter 2016 Financial Results](https://biopharmsignal.com/news/BMRN/biomarin-announces-third-quarter-2016-financial-results-ec8910d1) — Source: BioMarin Pharmaceutical
- 2016-10-19 21:01 EST — [BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting](https://biopharmsignal.com/news/BMRN/biomarin-presents-vosoritide-data-in-achondroplasia-at-american-society-of-human-fe9cc2ee) — Source: BioMarin Pharmaceutical
- 2016-10-13 20:01 EST — [UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study  of BMN 270 in Hemophilia A](https://biopharmsignal.com/news/BMRN/uk-regulatory-agency-approves-continued-enrollment-in-biomarin-phase-1-2-study-o-a82658cd) — Source: BioMarin Pharmaceutical